Last $2.32 USD
Change Today +0.06 / 2.65%
Volume 1.3M
RXII On Other Exchanges
Symbol
Exchange
NASDAQ CM
Frankfurt
NASDAQ CM
Frankfurt
As of 8:10 PM 09/12/14 All times are local (Market data is delayed by at least 15 minutes).

rxi pharmaceuticals (RXII) Snapshot

Open
$2.39
Previous Close
$2.26
Day High
$2.41
Day Low
$2.25
52 Week High
02/24/14 - $6.84
52 Week Low
09/10/14 - $2.15
Market Cap
37.4M
Average Volume 10 Days
1.7M
EPS TTM
$-2.22
Shares Outstanding
16.1M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for RXI PHARMACEUTICALS (RXII)

Related News

No related news articles were found.

rxi pharmaceuticals (RXII) Related Businessweek News

No Related Businessweek News Found

rxi pharmaceuticals (RXII) Details

RXi Pharmaceuticals Corporation, a biotechnology company, focuses on discovering, developing, and commercializing therapies based on its proprietary, next-generation RNA interference (RNAi) platform. The company’s lead product candidate, RXI-109, is a self-delivering RNAi compound, which is in Phase II clinical trial for use in the reduction of dermal scarring. Its therapeutic development programs in the discovery and preclinical stages include products for the treatment of ocular scarring, liver fibrosis, joint fibrosis, and vascular restenosis. The company was incorporated in 2011 and is headquartered in Marlborough, Massachusetts.

12 Employees
Last Reported Date: 03/28/14
Founded in 2011

rxi pharmaceuticals (RXII) Top Compensated Officers

Chief Executive Officer, President, Acting Ch...
Total Annual Compensation: $368.1K
Chief Development Officer
Total Annual Compensation: $324.4K
Compensation as of Fiscal Year 2013.

rxi pharmaceuticals (RXII) Key Developments

RXi Pharmaceuticals Corporation Reports Unaudited Earnings Results for the Second Quarter and Six Months Ended June 30, 2014

RXi Pharmaceuticals Corporation reported unaudited earnings results for the second quarter and six months ended June 30, 2014. For the quarter, the company reported total revenue of $12,000 compared with $225,000 for the same period a year ago. Operating loss was $2,021,000 against $1,965,000 a year ago. Net loss applicable to common stockholders of $3,219,000 or $0.23 per basic and diluted share compared with a net loss applicable to common stockholder of $4,360,000 or $0.39 per basic and diluted share for the comparable period in 2013. The decrease in net loss applicable to common stockholders of $1.2 million was primarily attributable to a decrease of $1.2 million in the fair value of dividends paid in additional preferred stock to the Company's preferred shareholders. For the six months, the company reported total revenue of $41,000 compared with $278,000 for the same period a year ago. Operating loss was $4,311,000 against $16,359,000 a year ago. Net loss applicable to common stockholders of $7,258,000 or $0.54 per basic and diluted share compared with a net loss applicable to common stockholder of $22,304,000 or $2.52 per basic and diluted share for the comparable period in 2013. The decrease in net loss applicable to common stockholders of $15.0 million was primarily attributable to the aforementioned decrease in net loss as compared to prior year and a decrease of $2.9 million in the fair value of dividends paid in additional preferred stock to the Company's preferred shareholders.

RXi Pharmaceuticals Expands Clinical Program with Initiation of Third Phase 2a Study with RXI-109 for Treatment of Hypertrophic Scars

RXi Pharmaceuticals Corporation announced that their third Phase 2a study (RXI-109-1402) with RXI-109, for the reduction of recurrence of hypertrophic scars following elective scar revision surgery, has been initiated. In this study (RXI-109-1402), patients with either one long hypertrophic scar, or two scars comparable in length, anatomical location and characteristics, are eligible to receive scar revision surgery. For a single scar, a portion of the revised scar segment will be treated with RXI-109 and a comparably sized length on the opposite end of the excised scar segment will be left untreated. If two scars are revised, a portion of one revised scar segment will be treated with RXI-109 and one scar will be left untreated after revision surgery. This third Phase 2a study will follow patients for nine months. Investigator and independent reviewer assessments will be used to evaluate the effectiveness of RXI-109 in preventing scar formation. Reviewers will evaluate and compare the appearance of the revised areas after treatment with RXI-109 or when left untreated. This design allows for intra-subject comparison thereby increasing the power of the study.

RXi Pharmaceuticals Appoints Peter Campochiaro to Scientific Advisory Board

RXi Pharmaceuticals Corporation announced the appointment of Dr. Peter Campochiaro to its Scientific Advisory Board. Campochiaro is the George S. and Dolores Dore Eccles Professor of Ophthalmology and Neuroscience in the Johns Hopkins University School of Medicine. He is a prominent researcher, clinician and educator in the field of ophthalmology. He sees patients at the Wilmer Eye Institute at Johns Hopkins. With more than 300 articles published in peer-reviewed medical journals, Dr. Campochiaro is a clinician-scientist who does both laboratory and clinical research. His major laboratory interest is in elucidating the molecular pathogenesis of ocular neovascularization and excessive vascular leakage. He has generated many animal models of retinal and choroidal vascular diseases that have been useful for evaluating drug and gene-based therapies. His laboratory helped to demonstrate the importance of vascular endothelial growth factor (VEGF) in retinal and choroidal vascular diseases and his clinical trial group performed many of the early phase studies evaluating VEGF antagonists. He serves on Scientific Advisory Board of several pharmaceutical companies.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
RXII:US $2.32 USD +0.06

RXII Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for RXII.
View Industry Companies
 

Industry Analysis

RXII

Industry Average

Valuation RXII Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 200.7x
Price/Book 15.6x
Price/Cash Flow NM Not Meaningful
TEV/Sales 99.8x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact RXI PHARMACEUTICALS, please visit www.rxipharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.